Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cisplatin dosing schedule comparison during chemoradiotherapy for head and neck squamous cell carcinoma
IRCT20201220049776N1Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cisplatin in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoints: Mucositis, Dysphagia and 1 more. Started Nov 2019; status: completed.
02
Drugs
cisplatin
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on IRCT20201220049776N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20201220049776N1.